Scientists at The Scripps Research Institute have shown that a particular white blood cell plays a direct role in the development and spread of cancerous tumors. Their work sheds new light on the development of the disease and points toward novel strategies for treating early-stage cancers.
The study was published in September 2011 print issue of the American Journal of Pathology.
Scripps Research Professor James Quigley, Staff Scientist Elena Deryugina, and colleagues had previously demonstrated that white blood cells known as neutrophils—bone marrow-derived cells that function as “first responders” at sites of acute inflammation—promote the growth of new blood vessels in normal, healthy tissue.
The team has now tied these cells to the induction and growth of new blood vessels in malignant tumors and to the spread of tumor cells through those newly formed vessels. The scientists have also uncovered some of the mechanisms underpinning this process—which could be interrupted by properly targeted drugs.
Potent and Uninhibited
The Scripps Research team has been particularly interested in neutrophils, in part because several studies have demonstrated a link between elevated neutrophil levels and high rates of tumor invasion among cancer patients. Mounting evidence has also indicated that neutrophils play a particularly important role during the early stages of tumor development.
“During tumor development, neutrophils appear to be one of the first inflammatory cell types on the scene,” said Deryugina, who spearheaded the new study.
The researchers have been especially interested in the blood vessel-forming or “angiogenic,” powers of neutrophils, which stem from a special enzyme they produce known as MMP-9 (matrix metalloproteinase type 9). The enzyme is, in fact, synthesized by a number of different types of white blood cells and has long been linked to tumor development. But the particular form synthesized by neutrophils is especially potent, in part because it does not come bound up with the natural inhibitory regulating agents that other cells supply.
Whereas other types of white blood cells only manufacture the enzyme later and invariably deliver it in combination with one of its natural inhibitors, neutrophils come loaded with pre-synthesized MMP-9 in a form that is unencumbered.
Making the Case
In a series of cleverly designed experiments, Quigley, Deryugina, and colleagues established a link between neutrophils, their MMP-9, and the growth and spread of tumors.
The scientists alternately raised and lowered the quantity of neutrophils allowed to flow into two different kinds of early-stage tumors, which had been transplanted into chicken embryos and mice. They also introduced several different versions of the enzyme, sometimes combining it with dampening agents, sometimes not.
By observing the subsequent decrease and increase in the formation of new blood vessels, the Scripps Research team was able to establish that the unique form of the enzyme delivered by neutrophils was directly responsible for heightening the growth of new blood vessels in the tumors. Just as importantly, they were able to determine that the newly formed blood vessels served as “escape routes” or conduits for the spread of tumor cells beyond their initial location.
First, the scientists established that the most aggressive tumors—that is, the ones that were able to most quickly penetrate the surrounding blood vessels and spread to different areas—depended on their ability to attract large numbers of neutrophils.
The researchers then proceeded to spur the growth of new blood vessels in even relatively nonaggressive tumors by supplying additional quantities of neutrophil-derived enzyme. They also blocked the formation of new vessels with the anti-inflammatory drug ibuprofen and then restored, or “rescued,” angiogenesis by pumping in additional enzyme.
Quigley and Deryugina also drastically reduced the influx of neutrophils by neutralizing IL-8 (interleukin 8), the chemical attractant that draws neutrophils to sites of inflammation. Blood vessel formation declined correspondingly, as did the penetration of vessels by tumor cells, clearly linking neutrophils to the development and spread of two different, but highly aggressive, forms of cancer. To further strengthen that link, the researchers again reversed the decline with an infusion of neutrophil-derived enzyme.
“By dampening neutrophil influx into tumors, we dampen angiogenesis, but we also dampen metastasis,” Quigley said. “And when we rescue angiogenesis, we also rescue the high metastatic rate of the tumors.”
Significantly, only the unregulated, uninhibited version of the enzyme provided by neutrophils reversed the dampening effect caused by reducing inflammation or cutting off the flow of neutrophils. No such rescue occurred when the enzyme was combined with its natural inhibiting agents—the same molecules that accompany the enzyme when it is delivered by other kinds of white blood cells.
The scientists note that the study suggests tumors that engender a strong inflammatory response may be particularly amenable to early-stage treatment by drugs that specifically target neutrophils, whether that means inhibiting the enzyme they deliver or simply preventing them from showing up in the first place.
“It might be best to combat tumor angiogenesis earlier rather than later,” Quigley said, adding that “more specifically directed anti-neutrophil agents might be better suited than a general anti-inflammatory.”
The Quigley lab continues to investigate.
In addition to Quigley and Deryugina, authors of this paper, “Neutrophil MMP-9 in Tumor Progression” (doi:10.1016/j.ajpath.2011.05.031), include Bernhard Schweighofer, Tatyana A. Kupriyanova, Ewa Zajac, Veronica C. Ardi, all of Scripps Research; and Erin M. Bekes, formerly a UCSD graduate student doing her thesis at Scripps Research and now a postdoctoral fellow at the NYU School of Medicine. See http://www.sciencedirect.com/science/article/pii/S000294401100530X
Support for this study came from the National Institutes of Health, Scripps Translational Science Institute, the Max Kade Foundation, and the National Cancer Institute.
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neuroscience, and vaccine development, as well as for its insights into autoimmune, cardiovascular, and infectious disease. Headquartered in La Jolla, California, the institute also includes a campus in Jupiter, Florida, where scientists focus on drug discovery and technology development in addition to basic biomedical science. Scripps Research currently employs about 3,000 scientists, staff, postdoctoral fellows, and graduate students on its two campuses. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, is ranked among the top ten such programs in the nation. For more information, see www.scripps.edu.For information:
Mika Ono | EurekAlert!
Rainbow colors reveal cell history: Uncovering β-cell heterogeneity
22.09.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden
The pyrenoid is a carbon-fixing liquid droplet
22.09.2017 | Max-Planck-Institut für Biochemie
Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.
A warming planet
Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.
The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...
Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
22.09.2017 | Life Sciences
22.09.2017 | Medical Engineering
22.09.2017 | Physics and Astronomy